Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
Brieva L, Estruch BC, Merino JAG, Meca-Lallana V, Río J, Rodríguez-Antigüedad A, Agüera E, Ara JR, Luque AA, Garcia CA, Blanco Y, Castillo-Triviño T, Costa-Frossard L, González Platas M, Pascual LL, Llaneza-González M, Ginés MLM, Matías-Guiu J, Meca-Lallana JE, Bilbao MM, Sempere AP, Romero-Pinel L, Saiz A, Moral E. Brieva L, et al. Among authors: gines mlm. Mult Scler Relat Disord. 2022 Jul;63:103805. doi: 10.1016/j.msard.2022.103805. Epub 2022 Apr 12. Mult Scler Relat Disord. 2022. PMID: 35512501 Review.
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
Vermersch P, Brieva-Ruiz L, Fox RJ, Paul F, Ramio-Torrenta L, Schwab M, Moussy A, Mansfield C, Hermine O, Maciejowski M; AB07002 Study Group. Vermersch P, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Feb 21;9(3):e1148. doi: 10.1212/NXI.0000000000001148. Print 2022 May. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35190477 Free PMC article. Clinical Trial.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study.
Pilo de la Fuente B, Sabín J, Galán V, Thuissard I, Sainz de la Maza S, Costa-Frossard L, Gómez-Moreno M, Díaz-Díaz J, Oreja-Guevara C, Lozano-Ros A, García-Domínguez JM, Borrego L, Ayuso L, Castro A, Sánchez P, Meca-Lallana V, Muñoz C, Casanova I, López de Silanes C, Martín H, Rodríguez-García E, Andreu-Vázquez C, Blasco R, García-Merino JA, Aladro Y; Dimethyl Fumarate Study Group. Pilo de la Fuente B, et al. CNS Drugs. 2020 Dec;34(12):1275-1286. doi: 10.1007/s40263-020-00775-9. Epub 2020 Nov 23. CNS Drugs. 2020. PMID: 33226562
MAU2 and NIPBL Variants Impair the Heterodimerization of the Cohesin Loader Subunits and Cause Cornelia de Lange Syndrome.
Parenti I, Diab F, Gil SR, Mulugeta E, Casa V, Berutti R, Brouwer RWW, Dupé V, Eckhold J, Graf E, Puisac B, Ramos F, Schwarzmayr T, Gines MM, van Staveren T, van IJcken WFJ, Strom TM, Pié J, Watrin E, Kaiser FJ, Wendt KS. Parenti I, et al. Among authors: gines mm. Cell Rep. 2020 May 19;31(7):107647. doi: 10.1016/j.celrep.2020.107647. Cell Rep. 2020. PMID: 32433956 Free article.
Pharmacokinetics of Subcutaneous Levetiracetam in Palliative Care Patients.
Papa P, Oricchio F, Ginés M, Maldonado C, Tashjian A, Ibarra M, Percovich M, Fagiolino P, Pedragosa B, Vázquez M. Papa P, et al. Among authors: gines m. J Palliat Med. 2021 Feb;24(2):248-251. doi: 10.1089/jpm.2019.0525. Epub 2020 Apr 8. J Palliat Med. 2021. PMID: 32267792
Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study.
Fabrellas N, Hernández R, Graupera I, Solà E, Ramos P, Martín N, Sáez G, Simón C, Pérez A, Graell T, Larrañaga A, Garcia M, de la Arada A, Juanola A, Coiduras A, Duaso I, Casado A, Martin J, Ginès M, Moreno N, Gema Perez A, Marti L, Bernat M, Sola M, Olivé C, Solé C, Ginès P. Fabrellas N, et al. Among authors: gines m. PLoS One. 2018 Sep 18;13(9):e0200656. doi: 10.1371/journal.pone.0200656. eCollection 2018. PLoS One. 2018. PMID: 30226889 Free PMC article. Clinical Trial.
Break-out session highlights.
Myhr KM, Mäurer M, Ginés MM, Esposito F, Linker R. Myhr KM, et al. Among authors: gines mm. Neurodegener Dis Manag. 2017 Nov;7(6s):45-49. doi: 10.2217/nmt-2017-0042. Neurodegener Dis Manag. 2017. PMID: 29143586
29 results